Abstract Library

#4356 Assessment of medium- and long-term side effects of Lu-177 treatment in patients with neuroendocrine tumours

Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,

Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,

#3557 Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,

#3216 Survey for neuroendocrine tumors’ standard of care - A multidisciplinary pilot study in Spanish specialists

Introduction: The standard of care for the treatment of neuroendocrine tumors (NETs) seems to have shifted over the last few years towards a multidisciplinary approach. In Spain, there is a lack of real-world data related to NET management in Medical NETs Specialist population.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Sampedro-Núñez M, Muñoz de Nova J, Vázquez G, Hernando J, Triviño E,

Keywords: online survey, patient care, clinical guidelines, research, training,

#3137 Empowerment survey for patients with neuroendocrine tumors - A pilot study in Spanish population

Introduction: Quality of life is very important in patients with neuroendocrine tumors (NET), but other aspects such as satisfaction and empowerment of patients have been less studied. In Spain, there is a lack of validated cancer empowerment questionnaires.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hernando J

Authors: Hernando J, Sampedro-Núñez M, Muñoz de Nova J, Triviño E, Vázquez G,

Keywords: empowerment, online survey, patient advocacy,

#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Munoz Medel M

Authors: Munoz-Medel M, Cordova Delgado M, Pinto M, Bravo M, Retamal I,

Keywords: Neuroendocrine, Chromogranin A, Biomarker,